Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis

Andrzej Bożek; Agnieszka Bogacz-Piaseczyńska; Martyna Miodońska; Dominika Sadowska

doi:10.5114/ada.2023.129942

eISSN: 2299-0046
ISSN: 1642-395X

Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii

Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

5/2023
vol. 40

Send email

Copy url:

abstract:

Original paper

Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis

Andrzej Bożek

¹

,

Agnieszka Bogacz-Piaseczyńska

¹

,

Martyna Miodońska

¹

,

Dominika Sadowska

¹

Clinical Department of Internal Medicine, Dermatology and Allergology in Zabrze, Medical University of Silesia in Katowice, Poland

Adv Dermatol Allergol 2023; XL (5): 688-692

DOI: https://doi.org/10.5114/ada.2023.129942

Online publish date: 2023/07/19

View full text Get citation

Introduction:
Allergen immunotherapy (AIT) is an effective therapy for allergic rhinitis and may have long-term benefits. However, these benefits have not been strictly defined for older people.

Aim:
The evaluation of the effectiveness of AIT in patients over 60 with allergic rhinitis and house dust mites (HDM) allergy over a period of 7 years was performed.

Material and methods:
Patients after three years of HDM-AIT were observed to assess the sustained clinical effect of treatment. The average adjusted symptom score (AAdSS) and sIgG4 were monitored for 7 years after sublingual (SLIT) and injection AIT (SCIT).

Results:
After 3 years of HDM-AIT, a significant clinical effect was observed in the group after SLIT and SCIT based on AAdSS compared to the baseline and the placebo group (p < 0.05). After 7 years of follow-up, there was a sustained trend of decrease in clinical symptoms in desensitized patients relative to placebo. Serum sIgG4 was constantly present in all desensitized patients.

Conclusions:
AIT may be beneficial for treating seniors with allergic rhinitis and allergies to house dust mites.

keywords:

Long-term benefit after allergen immunotherapy to HDM in elderly patients with allergic rhinitis

Andrzej Bożek 1 , Agnieszka Bogacz-Piaseczyńska 1 , Martyna Miodońska 1 , Dominika Sadowska 1

allergen immunotherapy, allergy, IgE, allergic rhinitis

Andrzej Bożek

¹

,

Agnieszka Bogacz-Piaseczyńska

¹

,

Martyna Miodońska

¹

,

Dominika Sadowska

¹